Baudax Bio Announces Partial Adjournment of Annual Meeting of Shareholders
April 08 2021 - 4:05PM
Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical
company focused on therapeutics for acute care settings, today
announced that it has adjourned its 2021 Annual Meeting of
Shareholders (the “Annual Meeting”) solely with respect to Proposal
3 set forth in its Definitive Proxy Statement (“Proxy Statement”)
filed with the Securities and Exchange Commission on March 11,
2021. Proposal 3 is a proposal to amend the Company’s Amended and
Restated Articles of Incorporation to increase the number of
authorized shares of common stock from 100 million shares to 190
million shares. The Company has adjourned the Annual Meeting with
respect to Proposal 3 to provide its shareholders additional time
to vote on Proposal 3. The Annual Meeting will resume with respect
to Proposal 3 at 10:00 a.m. Eastern time on May 6, 2021 and will
continue to be held virtually at
www.virtualshareholdermeeting.com/BXRX2021.
The record date for determining shareholders
eligible to vote at the annual meeting will remain the close of
business on March 1, 2021. Shareholders who have already submitted
a proxy do not need to vote again for the reconvened Annual
Meeting, as the proxies submitted will remain valid. Shareholders
who have already submitted proxies and want to change their vote
with respect to Proposal 3 can update their vote in the manner set
forth in the Proxy Statement. Your vote will be recorded at the
Annual Meeting in accordance with your most recently submitted
proxy.
Shareholders as of close of business on
the March 1, 2021 record date who have not voted are encouraged to
vote online at www.proxyvote.com or by telephone at 1-800-690-6903.
Shareholders needing assistance voting or have questions may
contact the Company’s proxy solicitation firm, Okapi Partners, at
info@okapipartners.com or (855) 208-8902.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on therapeutics for acute care settings. The launch of Baudax Bio’s
first commercial product ANJESO® began in June 2020 following its
approval by the U.S. Food and Drug Administration in February 2020.
ANJESO is a once daily IV NSAID with preferential Cox-2 activity,
which has successfully completed three Phase III clinical trials,
including two pivotal efficacy trials, a large double-blind Phase
III safety trial and other studies for the management of moderate
to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of
other pharmaceutical assets including two novel neuromuscular
blocking agents (NMBAs) and a proprietary chemical reversal agent
specific to these NMBAs which is currently in preclinical studies,
and intranasal dexmedetomidine which is being developed for
possible uses in pain or sedation. For more information please
visit www.baudaxbio.com.
Forward Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Baudax Bio’s expectations about
its future performance and opportunities that involve substantial
risks and uncertainties. When used herein, the words “anticipate,”
“believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal”,
“intend” and “expect” and similar expressions, as they relate to
Baudax Bio or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information available to Baudax Bio as of the date of
publication on this internet site and are subject to a number of
risks, uncertainties, and other factors that could cause Baudax
Bio’s performance to differ materially from those expressed in, or
implied by, these forward-looking statements. Baudax Bio assumes no
obligation to update any such forward-looking statements. These
forward-looking statements should be considered together with the
risks and uncertainties that may affect our business and future
results included in our filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking statements are
based on information currently available to us, and we assume no
obligation to update any forward-looking statements except as
required by applicable law. These forward looking statements should
be considered together with the risks and uncertainties that may
affect Baudax Bio’s business and future results included in Baudax
Bio’s filings with the Securities and Exchange Commission at
www.sec.gov.
CONTACT:
Investor Relations Contact:Argot PartnersSam Martin / Claudia
Styslinger(212) 600-1902baudaxbio@argotpartners.com
Media Contact:Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024